What is the global burden of preeclampsia?5 answersPreeclampsia poses a significant global burden, affecting 2% to 4% of pregnancies worldwide and leading to maternal morbidity and mortality, with up to 46,000 maternal and 500,000 fetal deaths annually, predominantly in low- and middle-income countries. The incidence of preeclampsia is notably higher in developing countries, such as India, where it accounts for over 50,000 maternal deaths and 500,000 fetal deaths globally. Risk factors for preeclampsia include demographic characteristics, medical history, and physiological abnormalities, emphasizing the importance of early identification and treatment during pregnancy. The condition contributes to serious complications like cardiovascular diseases in affected women, underscoring the necessity for preventive measures and high-quality antenatal care to mitigate adverse outcomes for both mothers and fetuses.
Cannabis user in pregnancy women5 answersCannabis use during pregnancy is a concerning issue. Studies have shown that the prevalence of cannabis use among pregnant women in the US ranges from 2.4% to 9.8%. Cannabis use during pregnancy has been associated with adverse outcomes for both the mother and the fetus. Maternal cannabis use has been linked to mental health disorders such as mood, anxiety, and post-traumatic stress disorders. It has also been associated with increased risk of adverse neonatal outcomes, including heart rhythm disorders and intrauterine growth restriction. The legalization of cannabis has led to an increase in its use among pregnant women. Online forums have become a source of information for cannabis-using pregnant women, who often do not seek counsel from healthcare providers due to stigma and legal concerns. Close monitoring and increased screening are necessary to address the potential effects of cannabis use during pregnancy.
What are the statistics on substance use in pregnancy?5 answersSubstance use in pregnancy is a significant concern with various statistics reported in the literature. The 2019 National Survey on Drug Use and Health found that 6% of pregnant women reported illicit drug use, 10% reported tobacco use, and 10% reported alcohol use. A retrospective study analyzing trends in substance use among pregnant women in the United States found that among the birthing population, 0.1% used alcohol, 0.9% had opioid use disorder, 1.4% used cannabis, 0.1% used sedatives, 0.2% used cocaine, 0.4% used other stimulants, and 0.2% had other psychoactive diagnoses. Another study using The Healthcare Cost and Utilization Project-Nationwide Inpatient Sample from 2004 to 2014 found that substance use complicated approximately 5% of all pregnancies, with amphetamine/methamphetamine, opioid, cannabis, and polysubstance use increasing over time. Additionally, a study using data from two states found that 48.1% of pregnant persons with a congenital syphilis pregnancy outcome reported substance use, with illicit use of opioids being six times more likely in this group.
What is the prevalence of amphetamine use in pregnancy?5 answersThe prevalence of amphetamine use in pregnancy is not explicitly mentioned in the provided abstracts.
What is the prevalence of endometriosis globally?5 answersThe prevalence of endometriosis globally is highly variable, with estimates ranging from 0.2% to 71.4% depending on the population sampled. In general population studies, the prevalence ranges from 0.7% to 8.6%. However, when defined by indications for diagnosis, the prevalence can be higher, ranging from 15.4% to 71.4% among women with chronic pelvic pain, 9.0% to 68.0% among women presenting with infertility, and 3.7% to 43.3% among women undergoing tubal sterilization. The overall prevalence of endometriosis in the general population is reported to be 5-10%. It is estimated that approximately 10% of reproductive age women suffer from endometriosis.
Is pregnant women more likely to have an opioid prescription?5 answersPregnant women are more likely to have an opioid prescription. Studies have shown that prescription opioid use among pregnant women has increased in recent years. Additionally, opioid prescribing rates for patients with opioid use disorder (OUD) or chronic pain were higher for vaginal birth compared to institutional averages. However, the prevalence of prescription opioid use among women of reproductive age has actually decreased over time. It is important for policy makers and clinicians to consider the demographic groups most likely to use prescription opioids long-term and to balance reductions in opioid prescribing with increased availability of nonopioid therapies and monitoring for opioid use disorder.